[go: up one dir, main page]

AU2001272598A1 - A method for treating septic shock - Google Patents

A method for treating septic shock

Info

Publication number
AU2001272598A1
AU2001272598A1 AU2001272598A AU7259801A AU2001272598A1 AU 2001272598 A1 AU2001272598 A1 AU 2001272598A1 AU 2001272598 A AU2001272598 A AU 2001272598A AU 7259801 A AU7259801 A AU 7259801A AU 2001272598 A1 AU2001272598 A1 AU 2001272598A1
Authority
AU
Australia
Prior art keywords
septic shock
treating septic
treatment
treating
levosimendan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001272598A
Inventor
Anders Oldner
Anders Rudehill
Michael Wanecek
Eddie Weitzberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Oyj filed Critical Orion Oyj
Publication of AU2001272598A1 publication Critical patent/AU2001272598A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Treatment Of Sludge (AREA)

Abstract

Levosimendan, or (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile, which has been mentioned for the treatment of congestive heart failure, is useful in the treatment of septic shock.
AU2001272598A 2000-06-29 2001-06-28 A method for treating septic shock Abandoned AU2001272598A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20001542A FI20001542L (en) 2000-06-29 2000-06-29 Method for treating septic shock
FI20001542 2000-06-29
PCT/FI2001/000614 WO2002000220A1 (en) 2000-06-29 2001-06-28 A method for treating septic shock

Publications (1)

Publication Number Publication Date
AU2001272598A1 true AU2001272598A1 (en) 2002-01-08

Family

ID=8558669

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001272598A Abandoned AU2001272598A1 (en) 2000-06-29 2001-06-28 A method for treating septic shock

Country Status (10)

Country Link
US (1) US7485642B2 (en)
EP (1) EP1294380B1 (en)
JP (1) JP4965791B2 (en)
AT (1) ATE272402T1 (en)
AU (1) AU2001272598A1 (en)
CA (1) CA2412213C (en)
DE (1) DE60104693T2 (en)
ES (1) ES2225580T3 (en)
FI (1) FI20001542L (en)
WO (1) WO2002000220A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20040674A0 (en) * 2004-05-12 2004-05-12 Orion Corp A method of inhibiting thromboembolic diseases
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
GB2266841A (en) * 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
FI981473L (en) * 1998-06-25 1999-12-26 Orion Yhtymae Oyj Method for treating pulmonary hypertension
GB9915179D0 (en) * 1999-06-29 1999-09-01 Orion Corp A method for the treatment or prevention of coronary graft vasospasm

Also Published As

Publication number Publication date
CA2412213C (en) 2009-04-14
JP4965791B2 (en) 2012-07-04
JP2004501194A (en) 2004-01-15
EP1294380B1 (en) 2004-08-04
WO2002000220A1 (en) 2002-01-03
US7485642B2 (en) 2009-02-03
ES2225580T3 (en) 2005-03-16
FI20001542A7 (en) 2001-12-30
FI20001542L (en) 2001-12-30
ATE272402T1 (en) 2004-08-15
EP1294380A1 (en) 2003-03-26
DE60104693D1 (en) 2004-09-09
US20030158201A1 (en) 2003-08-21
DE60104693T2 (en) 2005-08-11
CA2412213A1 (en) 2002-01-03
FI20001542A0 (en) 2000-06-29

Similar Documents

Publication Publication Date Title
AU2002316459A1 (en) Methods of treating cytokine mediated diseases
CA2134972A1 (en) Anti-ischemic medicament
NZ511594A (en) Process for making 5-substituted pyrazole derivatives using dithietanes
AU6142394A (en) New heterocyclic compounds, their preparation and their use
NZ507835A (en) Heterocyclic derivatives which inhibit factor XA
AU5320698A (en) Substituted dihydrobenzofurans as pde inhibitors
WO2001078653A3 (en) Graft rejection inhibition with ccr2 inhibitors
WO1999066912A3 (en) Method of treating pulmonary hypertension
AU2001272598A1 (en) A method for treating septic shock
GB9915179D0 (en) A method for the treatment or prevention of coronary graft vasospasm
WO1999055305A3 (en) Controlled release peroral compositions of levosimendan
CA2431125A1 (en) A method for treating erectile dysfunction
AU7928700A (en) A new use of levosimendan
DE69708645D1 (en) USE OF ASPIROCHLORINE OR DERIVATIVES FOR IMMUNE SUPPRESSION